{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:19:33Z","timestamp":1792801173672,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Liaoning Provincial Key Laboratory of Marine Bioactive Substances and Technological Innovation Center of Liaoning Pharmaceutical Action and Quality Evaluation","award":["Nos. 2022-8, 2022-12"],"award-info":[{"award-number":["Nos. 2022-8, 2022-12"]}]},{"name":"Jinzhou City Guiding Science and Technology Planning Project","award":["JZ2022B042"],"award-info":[{"award-number":["JZ2022B042"]}]},{"name":"Liaoning Province Applied Basic Research Program Joint Project","award":["2023021109-JH2\/1017"],"award-info":[{"award-number":["2023021109-JH2\/1017"]}]},{"name":"Scientific Research Project of the Educational Department of Liaoning Province","award":["LJKMZ20221249"],"award-info":[{"award-number":["LJKMZ20221249"]}],"id":[{"id":"https:\/\/ror.org\/0022v2454","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In this study, we prepared a bionic nanosystem of trastuzumab-functionalized SK-BR-3 cell membrane hybrid liposome-coated pyrotinib (Ptb-M-Lip-Her) for the treatment of HER2-positive breast cancer. Transmission electron microscopy, dynamic light scattering, polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting were used to verify the successful preparation of Ptb-M-Lip-Her. In vitro drug release experiments proved that Ptb-M-Lip-Her had a sustained release effect. Cell uptake experiments and in vivo imaging experiments proved that Ptb-M-Lip-Her had good targeting ability to homologous tumor cells (SK-BR-3). The results of cell experiments such as MTT, flow cytometry, immunofluorescence staining and in vivo antitumor experiments showed that Ptb-M-Lip-Her could significantly promote apoptosis and inhibit the proliferation of SK-BR-3 cells. These results clearly indicated that Ptb-M-Lip-Her may be a promising biomimetic nanosystem for targeted therapy of HER2-positive breast cancer.<\/jats:p>","DOI":"10.1186\/s13058-024-01853-2","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T06:02:08Z","timestamp":1718172128000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Jiaqun","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"issue":"19","key":"1853_CR1","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1002\/cncr.33102","volume":"126","author":"S Kunte","year":"2020","unstructured":"Kunte S, Abraham J, Montero AJ. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer. 2020;126(19):4278\u201388. https:\/\/doi.org\/10.1002\/cncr.33102.","journal-title":"Cancer"},{"issue":"3","key":"1853_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323.","journal-title":"JAMA"},{"key":"1853_CR3","doi-asserted-by":"publisher","unstructured":"Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer [published correction appears in Lancet. 2021 May 8;397(10286):1710]. Lancet. 2021;397(10286):1750\u20131769. https:\/\/doi.org\/10.1016\/S0140-6736(20)32381-3","DOI":"10.1016\/S0140-6736(20)32381-3"},{"issue":"2","key":"1853_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/ijms22020779","volume":"22","author":"S Pallerla","year":"2021","unstructured":"Pallerla S, Abdul AURM, Comeau J, Jois S. Cancer vaccines, treatment of the future: with emphasis on HER2-positive breast cancer. Int J Mol Sci. 2021;22(2):779. https:\/\/doi.org\/10.3390\/ijms22020779.","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"1853_CR5","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.breast.2022.01.006","volume":"62","author":"N Harbeck","year":"2022","unstructured":"Harbeck N. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. Breast. 2022;62(Suppl 1):S12\u20136. https:\/\/doi.org\/10.1016\/j.breast.2022.01.006.","journal-title":"Breast"},{"issue":"1","key":"1853_CR6","doi-asserted-by":"publisher","first-page":"e13352","DOI":"10.1111\/ecc.13352","volume":"30","author":"SA Jacob","year":"2021","unstructured":"Jacob SA, Do V, Wilson BE, Ng WL, Barton MB. The value of first-line chemotherapy and targeted therapy in the treatment of breast cancer. Eur J Cancer Care (Engl). 2021;30(1):e13352. https:\/\/doi.org\/10.1111\/ecc.13352.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"2","key":"1853_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.bbcan.2019.04.006","volume":"1871","author":"PY Liyanage","year":"2019","unstructured":"Liyanage PY, Hettiarachchi SD, Zhou Y, et al. Nanoparticle-mediated targeted drug delivery for breast cancer treatment. Biochim Biophys Acta Rev Cancer. 2019;1871(2):419\u201333. https:\/\/doi.org\/10.1016\/j.bbcan.2019.04.006.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1853_CR8","doi-asserted-by":"publisher","first-page":"gzab030","DOI":"10.1093\/protein\/gzab030","volume":"34","author":"T Lamtha","year":"2021","unstructured":"Lamtha T, Tabtimmai L, Bangphoomi K, et al. Generation of a nanobody against HER2 tyrosine kinase using phage display library screening for HER2-positive breast cancer therapy development. Protein Eng Des Sel. 2021;34:gzab030. https:\/\/doi.org\/10.1093\/protein\/gzab030.","journal-title":"Protein Eng Des Sel"},{"issue":"1","key":"1853_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-021-00629-w","volume":"6","author":"G Zheng","year":"2021","unstructured":"Zheng G, Guo Z, Li W, et al. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab. Signal Transduct Target Ther. 2021;6(1):236. https:\/\/doi.org\/10.1038\/s41392-021-00629-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"1853_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1159\/000512328","volume":"15","author":"C Dormann","year":"2020","unstructured":"Dormann C. Metastatic human epidermal growth factor receptor 2-positive breast cancer: current treatment standards and future perspectives. Breast Care (Basel). 2020;15(6):570\u20138. https:\/\/doi.org\/10.1159\/000512328.","journal-title":"Breast Care (Basel)"},{"issue":"12","key":"1853_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/biom9120789","volume":"9","author":"TM Abu Samaan","year":"2019","unstructured":"Abu Samaan TM, Samec M, Liskova A, Kubatka P, B\u00fcsselberg D. Paclitaxel\u2019s mechanistic and clinical effects on breast cancer. Biomolecules. 2019;9(12):789. https:\/\/doi.org\/10.3390\/biom9120789.","journal-title":"Biomolecules"},{"issue":"1","key":"1853_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ. HER2-targeted therapies\u2014a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33\u201348. https:\/\/doi.org\/10.1038\/s41571-019-0268-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"1853_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120716","volume":"271","author":"X Zheng","year":"2021","unstructured":"Zheng X, Zhao Y, Jia Y, et al. Biomimetic co-assembled nanodrug of doxorubicin and berberine suppresses chemotherapy-exacerbated breast cancer metastasis. Biomaterials. 2021;271: 120716. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.120716.","journal-title":"Biomaterials"},{"issue":"10","key":"1853_CR14","first-page":"2103","volume":"9","author":"JC Xuhong","year":"2019","unstructured":"Xuhong JC, Qi XW, Zhang Y, Jiang J. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res. 2019;9(10):2103\u201319.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"1853_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3892\/etm.2021.11037","volume":"23","author":"G Iancu","year":"2022","unstructured":"Iancu G, Serban D, Badiu CD, et al. Tyrosine kinase inhibitors in breast cancer (review). Exp Ther Med. 2022;23(2):114. https:\/\/doi.org\/10.3892\/etm.2021.11037.","journal-title":"Exp Ther Med"},{"issue":"12","key":"1853_CR16","doi-asserted-by":"publisher","first-page":"e1909","DOI":"10.1002\/onco.13546","volume":"25","author":"J Xuhong","year":"2020","unstructured":"Xuhong J, Qi X, Tang P, et al. Neoadjuvant Pyrotinib plus trastuzumab and chemotherapy for stage I-III HER2-positive breast cancer: a phase II clinical trial. Oncologist. 2020;25(12):e1909\u201320. https:\/\/doi.org\/10.1002\/onco.13546.","journal-title":"Oncologist"},{"issue":"1","key":"1853_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","volume":"7","author":"I Schlam","year":"2021","unstructured":"Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast Cancer. 2021;7(1):56. https:\/\/doi.org\/10.1038\/s41523-021-00265-1.","journal-title":"NPJ Breast Cancer"},{"issue":"12","key":"1853_CR18","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.21037\/gs-21-794","volume":"10","author":"Q Li","year":"2021","unstructured":"Li Q, Wang Y, Zhu M, Gu Y, Tang Y. Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study. Gland Surg. 2021;10(12):3389\u2013402. https:\/\/doi.org\/10.21037\/gs-21-794.","journal-title":"Gland Surg"},{"issue":"1","key":"1853_CR19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1186\/s12885-021-08759-8","volume":"21","author":"X Ai","year":"2021","unstructured":"Ai X, Song Z, Jian H, et al. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial. BMC Cancer. 2021;21(1):1033. https:\/\/doi.org\/10.1186\/s12885-021-08759-8.","journal-title":"BMC Cancer"},{"issue":"1","key":"1853_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.21037\/apm-21-3978","volume":"11","author":"C Fang","year":"2022","unstructured":"Fang C, Wen J, Kang M, Zhang Y, Chen Q, Ren L. Incidence and management of pyrotinib-associated diarrhea in HER2-positive advanced breast cancer patients. Ann Palliat Med. 2022;11(1):210\u20136. https:\/\/doi.org\/10.21037\/apm-21-3978.","journal-title":"Ann Palliat Med"},{"issue":"10","key":"1853_CR21","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1002\/2211-5463.13468","volume":"12","author":"R Kusumastuti","year":"2022","unstructured":"Kusumastuti R, Kumagai Y, Ishihara S, et al. Mammaglobin 1 mediates progression of trastuzumab-resistant breast cancer cells through regulation of cyclins and NF-\u03baB. FEBS Open Bio. 2022;12(10):1797\u2013813. https:\/\/doi.org\/10.1002\/2211-5463.13468.","journal-title":"FEBS Open Bio"},{"issue":"38","key":"1853_CR22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205454119","volume":"119","author":"S Kumar","year":"2022","unstructured":"Kumar S, Das S, Sun J, et al. Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles. Proc Natl Acad Sci USA. 2022;119(38): e2205454119. https:\/\/doi.org\/10.1073\/pnas.2205454119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1853_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2020.102338","volume":"35","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Ma X, Zhang R, et al. A novel liposome-polymer hybrid nanoparticles delivering a multi-epitope self-replication DNA vaccine and its preliminary immune evaluation in experimental animals. Nanomedicine. 2021;35: 102338. https:\/\/doi.org\/10.1016\/j.nano.2020.102338.","journal-title":"Nanomedicine"},{"issue":"11","key":"1853_CR24","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1021\/acsmacrolett.1c00558","volume":"10","author":"NM Hamelmann","year":"2021","unstructured":"Hamelmann NM, Paats JD, Paulusse JMJ. Cytosolic delivery of single-chain polymer nanoparticles. ACS Macro Lett. 2021;10(11):1443\u20139. https:\/\/doi.org\/10.1021\/acsmacrolett.1c00558.","journal-title":"ACS Macro Lett"},{"key":"1853_CR25","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2147\/IJN.S348598","volume":"17","author":"J Du","year":"2022","unstructured":"Du J, Zong L, Li M, et al. Two-pronged anti-tumor therapy by a new polymer-paclitaxel conjugate micelle with an anti-multidrug resistance effect. Int J Nanomed. 2022;17:1323\u201341. https:\/\/doi.org\/10.2147\/IJN.S348598.","journal-title":"Int J Nanomed"},{"key":"1853_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jconrel.2021.02.016","volume":"332","author":"B Ghosh","year":"2021","unstructured":"Ghosh B, Biswas S. Polymeric micelles in cancer therapy: state of the art. J Control Release. 2021;332:127\u201347. https:\/\/doi.org\/10.1016\/j.jconrel.2021.02.016.","journal-title":"J Control Release"},{"issue":"3","key":"1853_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3390\/polym13030370","volume":"13","author":"F Chen","year":"2021","unstructured":"Chen F, Li Y, Lin X, Qiu H, Yin S. Polymeric systems containing supramolecular coordination complexes for drug delivery. Polymers (Basel). 2021;13(3):370. https:\/\/doi.org\/10.3390\/polym13030370.","journal-title":"Polymers (Basel)"},{"key":"1853_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120362","volume":"597","author":"D Costa","year":"2021","unstructured":"Costa D, Santo D, Domingues C, Veiga F, Faneca H, Figueiras A. Recent advances in peptide-targeted micelleplexes: current developments and future perspectives. Int J Pharm. 2021;597: 120362. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120362.","journal-title":"Int J Pharm"},{"key":"1853_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jconrel.2020.12.036","volume":"330","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Liang J, Gao C, et al. Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy. J Control Release. 2021;330:641\u201357. https:\/\/doi.org\/10.1016\/j.jconrel.2020.12.036.","journal-title":"J Control Release"},{"key":"1853_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jconrel.2021.09.024","volume":"339","author":"S Moghassemi","year":"2021","unstructured":"Moghassemi S, Dadashzadeh A, Azevedo RB, Feron O, Amorim CA. Photodynamic cancer therapy using liposomes as an advanced vesicular photosensitizer delivery system. J Control Release. 2021;339:75\u201390. https:\/\/doi.org\/10.1016\/j.jconrel.2021.09.024.","journal-title":"J Control Release"},{"key":"1853_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113974","volume":"178","author":"J Wang","year":"2021","unstructured":"Wang J, Zhu M, Nie G. Biomembrane-based nanostructures for cancer targeting and therapy: From synthetic liposomes to natural biomembranes and membrane-vesicles. Adv Drug Deliv Rev. 2021;178: 113974. https:\/\/doi.org\/10.1016\/j.addr.2021.113974.","journal-title":"Adv Drug Deliv Rev"},{"key":"1853_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jcis.2022.07.006","volume":"627","author":"L Chiappisi","year":"2022","unstructured":"Chiappisi L, Hoffmann I, Gradzielski M. Membrane stiffening in Chitosan mediated multilamellar vesicles of alkyl ether carboxylates. J Colloid Interface Sci. 2022;627:160\u20137. https:\/\/doi.org\/10.1016\/j.jcis.2022.07.006.","journal-title":"J Colloid Interface Sci"},{"issue":"1","key":"1853_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s12951-022-01609-0","volume":"20","author":"H Ye","year":"2022","unstructured":"Ye H, Hu X, Wen Y, et al. Exosomes in the tumor microenvironment of sarcoma: from biological functions to clinical applications. J Nanobiotechnol. 2022;20(1):403. https:\/\/doi.org\/10.1186\/s12951-022-01609-0.","journal-title":"J Nanobiotechnol"},{"issue":"11","key":"1853_CR34","doi-asserted-by":"publisher","first-page":"10049","DOI":"10.1021\/acsnano.6b04695","volume":"10","author":"Z Chen","year":"2016","unstructured":"Chen Z, Zhao P, Luo Z, et al. Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano. 2016;10(11):10049\u201357. https:\/\/doi.org\/10.1021\/acsnano.6b04695.","journal-title":"ACS Nano"},{"issue":"16","key":"1853_CR35","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.3390\/molecules26165103","volume":"26","author":"Y Fan","year":"2021","unstructured":"Fan Y, Hao W, Cui Y, et al. Cancer cell membrane-coated nanosuspensions for enhanced chemotherapeutic treatment of glioma. Molecules. 2021;26(16):5103. https:\/\/doi.org\/10.3390\/molecules26165103.","journal-title":"Molecules"},{"key":"1853_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122285","volume":"628","author":"J An","year":"2022","unstructured":"An J, Jiang X, Wang Z, et al. Codelivery of minocycline hydrochloride and dextran sulfate via bionic liposomes for the treatment of spinal cord injury. Int J Pharm. 2022;628: 122285. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122285.","journal-title":"Int J Pharm"},{"key":"1853_CR37","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3389\/fimmu.2019.01078","volume":"10","author":"H Harjunp\u00e4\u00e4","year":"2019","unstructured":"Harjunp\u00e4\u00e4 H, Llort Asens M, Guenther C, Fagerholm SC. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front Immunol. 2019;10:1078. https:\/\/doi.org\/10.3389\/fimmu.2019.01078.","journal-title":"Front Immunol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01853-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-024-01853-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01853-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T06:15:52Z","timestamp":1718172952000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-024-01853-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1853"],"URL":"https:\/\/doi.org\/10.1186\/s13058-024-01853-2","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"assertion":[{"value":"19 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol was checked by the Animal Ethical and Welfare Committee (the rodent license NO.2022101601), and experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed to submit this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}